Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

NCT ID: NCT01539239

Last Updated: 2021-03-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1143 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is a prospective, randomized, controlled, multicenter, study. After informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity. Following successful screening, use of all topical glaucoma medications will be stopped for a period of "washout" to establish a qualifying medication-free intraocular pressure (IOP) value. Clinical follow up will be scheduled over the course of the 24 month study, and examinations will be repeated to monitor eye health. At the 1 and 2 year follow up, those patients on ocular hypotensive medications will be instructed to washout, and then have the diurnal (IOP taken in the morning, mid-day, and afternoon in the same day) IOP evaluation. Annual follow up will occur up to 5 years. The primary effectiveness endpoint is a decrease in diurnal IOP from baseline compared to the 24 months diurnal IOP following medication washout.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydrus Aqueous Implant (Treatment)

Cataract surgery plus Hydrus Aqueous Implant

Group Type EXPERIMENTAL

Hydrus Aqueous Implant

Intervention Type DEVICE

The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.

Cataract Surgery (Control)

Cataract surgery only

Group Type ACTIVE_COMPARATOR

Cataract surgery

Intervention Type PROCEDURE

A monofocal intraocular lens (IOL) placed during the cataract surgery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydrus Aqueous Implant

The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.

Intervention Type DEVICE

Cataract surgery

A monofocal intraocular lens (IOL) placed during the cataract surgery.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* An operable age-related cataract
* A diagnosis of POAG treated with 1 to 4 hypotensive medications
* Medicated IOP ≤ 31 mmHg
* Diurnal IOP ≥ 22 mmHg and ≤ 34 mmHg

Exclusion Criteria

* Congenital or developmental glaucoma
* Previous argon laser trabeculoplasty
* Ab-interno or ab-externo device implanted in or through Schlemm's Canal
* Use of oral hypotensive medication for glaucoma for treatment of fellow eye
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ivantis, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alan Crandall, MD

Role: PRINCIPAL_INVESTIGATOR

The Eye institute of Utah

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Phoenix, Arizona, United States

Site Status

Tucson, Arizona, United States

Site Status

Fayetteville, Arkansas, United States

Site Status

La Jolla, California, United States

Site Status

Orange, California, United States

Site Status

Sacramento, California, United States

Site Status

Fort Collins, Colorado, United States

Site Status

Parker, Colorado, United States

Site Status

Bradenton, Florida, United States

Site Status

Fort Myers, Florida, United States

Site Status

Ocala, Florida, United States

Site Status

Sioux City, Iowa, United States

Site Status

Garden City, Kansas, United States

Site Status

Louisville, Kentucky, United States

Site Status

Sandwich, Massachusetts, United States

Site Status

Bloomington, Minnesota, United States

Site Status

Chesterfield, Missouri, United States

Site Status

Wilmington, North Carolina, United States

Site Status

Cleveland, Ohio, United States

Site Status

Mason, Ohio, United States

Site Status

Maryville, Tennessee, United States

Site Status

Austin, Texas, United States

Site Status

Dallas, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Racine, Wisconsin, United States

Site Status

Edmonton, Alberta, Canada

Site Status

Boisbriand, Quebec, Canada

Site Status

Mainz, , Germany

Site Status

Parma, , Italy

Site Status

Tijuana, , Mexico

Site Status

Manila, , Philippines

Site Status

Warsaw, , Poland

Site Status

Madrid, , Spain

Site Status

Zaragoza, , Spain

Site Status

London, , United Kingdom

Site Status

Manchester, , United Kingdom

Site Status

Norwich, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Germany Italy Mexico Philippines Poland Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Zebardast N, Zheng C, Jampel HD. Effect of a Schlemm's Canal Microstent on Early Postoperative Intraocular Pressure after Cataract Surgery: An Analysis of the HORIZON Randomized Controlled Trial. Ophthalmology. 2020 Oct;127(10):1303-1310. doi: 10.1016/j.ophtha.2020.01.025. Epub 2020 Jan 23.

Reference Type DERIVED
PMID: 32143828 (View on PubMed)

Samuelson TW, Chang DF, Marquis R, Flowers B, Lim KS, Ahmed IIK, Jampel HD, Aung T, Crandall AS, Singh K; HORIZON Investigators. A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. Ophthalmology. 2019 Jan;126(1):29-37. doi: 10.1016/j.ophtha.2018.05.012. Epub 2018 Jun 23.

Reference Type DERIVED
PMID: 29945799 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP-11-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hydrus Learning Curve Study
NCT06964139 COMPLETED